Abstract
Acenocoumarol is mainly catabolized by CYP2C9 isoform of cytochrome P450 (CYP) liver complex and exerts its anticoagulant effect through the inhibition of Vitamin K Epoxide Reductase (VKOR). The most important genetic polymorphisms which lead to an impaired enzymatic activity and therefore predispose to acenocoumarol sensitivity, are considered to be CYP2C9*2 (Arg144Cys), CYP2C9*3 (Ile359Leu) and VKORC1-1639G>A, respectively. In this study we compared the results of the PGXThrombo StripAssay kit (ViennaLab Diagnostics,Vienna, Austria) with direct DNA sequencing and in house Restriction Fragment Length Polymorphisms (RFLP) for the detection of the aforementioned Single Nucleotide Polymorphisms (SNPs). The reverse hybridization StripAssay was found to be equally effective with RFLP and direct DNA sequencing for the detection of CYP2C9*2 and CYP2C9*3 polymorphisms, respectively. The comparison of the RFLP reference method with the reverse hybridization StripAssay for the detection of VKORC1-1639 G>A polymorphism showed that the reverse hybridization StripAsssay might misclassify some A/A homozygotes as heterozygotes. Optimization of the hybridization procedures may eliminate the extra low signal band observed in some samples at the reverse hybridization StripAssay and improve its diagnostic value.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ansell J, Hirsch J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists; the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(Suppl 3):204S–233S. doi:10.1378/chest.126.3_suppl.204S
Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J (2006) The c.-1639G>A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133:183–187. doi:10.1111/j.1365-2141.2006.06007.x
Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, Rocha E (2002) Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99:4237–4239. doi:10.1182/blood.V99.11.4237
Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH (2006) A case study of acenocoumarol sensitivity and genotype–phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol 62:617–620. doi:10.1111/j.1365-2125.2006.02688.x
Bodin L, Verstuyft C, Tregouet D, Robert A, Dubert L, Funck-Brentano C et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135–140. doi:10.1182/blood-2005-01-0341
Voora D, McLeod HL, Eby C, Gage BF (2005) The pharmacogenetics of coumarin therapy. Pharmacogenomics 6:503–513. doi:10.2217/14622416.6.5.503
Oldenburg J, Watzka M, Rost S, Müller C (2007) VKORC1: molecular target of coumarins. J Thromb Haemost 5:1–6. doi:10.1111/j.1538-7836.2007.02549.x
Oldenburg J, Bevans G, Fregin A, Geisen C, Müller-Reible C, Watzka M (2007) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 98:570–578
Yuan H, Chen J, Lee M, Wung J, Chen Y (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745–1751. doi:10.1093/hmg/ddi180
Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr (2008) Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9:169–178. doi:10.2217/14622416.9.2.169
Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819
Markatos CN, Grouzi E, Politou M, Gialeraki A, Merkouri E, Panagou I, Spiliotopoulou I, Travlou A (2008) VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 9:1631–1638. doi:10.2217/14622416.9.11.1631
Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99–111. doi:10.1038/sj.tpj.6500417
Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-Rationale and perspectives. Thromb Res 120:1–10. doi:10.1016/j.thromres.2006.10.021
Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadians Native Indians and Inuit populations. Can J Physiol Pharmacol 79:841–847. doi:10.1139/cjpp-79-10-841
Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Rohn HK, Wennerholm A (2002) Analysis of CYP2C9*5 in Caucasians, Oriental and black-African populations. Eur J Clin Pharmacol 58:555–558. doi:10.1007/s00228-002-0518-6
D’Andrea G, D’Ambrosio R, Margaglione M (2008) Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev 22:127–140. doi:10.1016/j.blre.2007.11.004
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gialeraki, A., Markatos, C., Grouzi, E. et al. Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep 37, 1693–1697 (2010). https://doi.org/10.1007/s11033-009-9587-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-009-9587-2